Prempro

Since breast cancer is much more common than endometrial cancer, combined HRT poses the greatest overall cancer risk." The British study recruited women aged 50 to 64 who were cancer-free at baseline.

Upon entry into the study, the women provided information about their use of HRT and other personal details.

They were classified according to whether they had ever used HRT, age at first and last use, total duration of use, and the name of the preparation last used, and the duration of its use.

The women were followed up for an average of more than three years (through the end of 2002).

There were 1,320 endometrial cancers diagnosed.

Forty-five percent of the women used HRT at baseline.

Of those 320,953 women, 22% used continuous combination therapy, 45% used cyclic combination therapy (estrogen daily with progestin added for 10 to 14 days per month), and 4% used estrogen only HRT.

Another 9% used a synthetic hormone, tibolone, which is not available in the U.S.

Among the findings: For women with a BMI <25 kg/m2, the use of cyclic comb...

Read more...